Zamansky LLC announces that it is investigating Zafgen, Inc. (NASDAQ:ZFGN) (Zafgen or the Company) for potential breaches of fiduciary duties by its officers and board of directors. If you are a shareholder of Zafgen who still holds your shares, please contact our firm for information.
It has recently emerged from public filings that Zafgen has received a letter from the U.S. Food and Drug Administration (FDA) citing possible cardiovascular safety risks associated with the clinical trial of a new type 2 diabetes drug ZGN-1061 as the reason for placing a clinical hold on the trial.
According to Jake Zamansky, investment fraud attorney, part of the fiduciary duties owed by Zafgens officers and directors to the Company and its shareholders is the obligation to avoid such potentially dangerous conduct.
What Zafgen Shareholders Can Do
If you are a current shareholder of Zafgen who still holds your stock, please contact us to review or discuss your legal rights. You may, without obligation or cost to you, email [email protected] or call the law firm at (212) 742-1414.
About Zamansky LLC
Zamansky LLC is a leading investment fraud law firm with experience handling securities, hedge fund, ERISA and other shareholder class action and derivative litigation. We are investment fraud attorneys who represent both individual and institutional investors. Our practice is nationally recognized for our ability to aggressively prosecute cases and recover investment losses.
To learn more about Zamansky LLC, please visit our website, http://www.zamansky.com.
50 Broadway – 32nd Floor
New York, NY 10004